Press "Enter" to skip to content

Pfizer to buy cancer drug developer Array for $10.64 billion

The offer of $48 per Array share represents a premium of about 62% to the stock’s close on Friday. Array’s shares surged 56% in light premarket trade.

Original source:

Also Read:   US health regulator finds Silvassa unit non-compliant with CGMP: Ipca Labs